EXHIBIT 1.
Characteristics Of The Study Sample Before October 2010: Women Ages 19–25 (Study Group) And Women Age 18 Or 26 (Control Group)
| Study: ages 19–25 | Control: age 18 or 26 | ||
|---|---|---|---|
| DEPENDENT VARIABLES | |||
| Insurance coverage | |||
| Any insurance coverage | 73.69% | 82.53%*** | |
| Awareness | |||
| Heard of HPV | 79.18% | 78.58% | |
| Heard of HPV vaccine | 74.94 | 77.26 | |
| Vaccination status | |||
| Vaccine initiation | 15.87% | 23.83%*** | |
| Vaccine completion | 8.85 | 15.25*** | |
| INDEPENDENT VARIABLES | |||
| Age (years) | 22.02 | 22.12 | |
| Married | 21.32% | 22.68% | |
| Race/ethnicitya | |||
| Non-Hispanic white | 60.68% | 63.78% | |
| Non-Hispanic black | 15.87 | 14.25 | |
| Hispanic | 17.29 | 16.87 | |
| Asian/other | 6.16 | 5.11 | |
| Health status, self-reporteda | |||
| Excellent | 42.56% | 43.03% | |
| Very good | 33.25 | 33.23 | |
| Good or fair/poor | 24.17 | 24.75 |
SOURCE Authors’ analysis of data from the National Health Interview Survey, first quarter 2008–third quarter 2010. NOTES The sample size for the pre-policy implementation period included 3,814 women ages 19–25 and 1,004 women age 18 or 26. All figures are mean percentages, except for age, which is mean years of age. A person was considered to have completed the three-dose vaccine series if she reported receipt of three or more doses of the vaccine. Significance indicates a difference of the control group from the study group, based on t-tests. HPV is human papillomavirus.
There were no significant associations between being ages 19–25 versus 18 or 26 and race or health status based on Pearson’s chi-square test statistic corrected for survey design.
p<0:01